Tax is the drug again as US rival bids £27bn for Shire
Jim Armitage is the City editor of The Independent and London Evening Standard group of newspapers. He has been a reporter and editor for more than 20 years and was recently shortlisted for the Press Gazette financial journalist of the year and The Society of Editors financial journalist of the year awards. He contributes news, investigative reports and comment to the Independent titles plus a daily column in the Evening Standard.
Deputy Business editor
Saturday 21 June 2014
A second US drugs company has followed Pfizer in trying to buy a FTSE 100 giant in the hope of moving its tax base to Britain. AbbVie, until recently a division of Abbot Laboratories, has offered £27bn to buy Shire Pharmaceuticals, famed for its medicines for attention deficit disorder and rare diseases.
Shire moved to Ireland in 2008 to save tax but, just like Pfizer with AstraZeneca, AbbVie wants to merge its operations and move the domicile to the UK so it can benefit from Britain’s new-found tax- haven status.
The tax trick would not work if the combined group remained in Ireland, because US laws mean companies can only carry out such “inversion” deals with their tax domicile if at least a fifth of their shareholders are based in the new country.
UK corporate taxes are lower than in most developed economies, while patented products such as medicines carry further tax breaks.
Shire said it had rejected offers from AbbVie on 5 May, 13 May and 30 May, claiming they “fundamentally” undervalued its prospects. For the first time, it declared it would double sales to $10m (£6m) by 2020.
Shire says its fortunes have been transformed by its move into rare diseases, where sales of its medicines are running 39 per cent above last year.
AbbVie’s offer was priced at £46.11 per Shire share in cash and paper. Although based in Ireland now, Shire’s shares still trade on the London Stock Exchange.
While the takeover appears to have the hallmarks of the AstraZeneca takeover tussle, it does not have the same political ramifications.
Unlike AstraZeneca, Shire has no significant research and development presence in the UK, only employing about 400 staff in its Basingstoke head office. Its R&D scientists, who number about 1,700, are mostly in Massachusetts.
Nevertheless, AbbVie has hired the same political and media advisers as Pfizer used on its own bid – Sir Alan Parker’s Brunswick. Again like Pfizer, its panel of advisers include JPMorgan. Shire is using the banks Citi, Evercore and Morgan Stanley for its defence.
AbbVie’s blockbuster medicine is a treatment for rheumatoid arthritis called Humira, which is by some counts the biggest-selling medicine in the world. But this will begin losing its patent protection in the US and Europe in the next few years, and analysts said yesterday that Shire would provide AbbVie with the diversification it needs.
Shire’s share price leapt 17 per cent to 4,371p yesterday, and those close to the US company said it was considering a higher offer, possibly as early as next week.
At the latest price, the personal stake of Shire’s chief executive, Flemming Ornskov, would be worth £1m and his options would have a value of just under £2m.
- 3 Alton Towers crash: Four seriously injured and 16 guests trapped as Smiler ride carriages collide
- 4 Ann Summers survey reveals the UK's favourite sex position
Man on naked bike ride gets ejected after becoming aroused
Caitlyn Jenner's mother Ester thought her daughter, formerly known as Bruce Jenner, had transitioned for money
Charles Kennedy 1959-2015: A gifted, compassionate politician whose career was cut short by the 'demon drink' - latest news
Alton Towers crash: Four seriously injured and 16 guests trapped as Smiler ride carriages collide
Charles Kennedy dead: A guy once asked the Lib Dem leader who his favourite Muppet was and his letter response was wonderful
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Church of England 'one generation away from extinction' after dramatic loss of followers
iJobs Money & Business
£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...
£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...
£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...
£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...